Connection

Charles Bennett to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications Charles Bennett has written about Imatinib Mesylate.
Charles Bennett
Connection Strength
0.081
Imatinib Mesylate
  1. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5.
    View in: PubMed
    Score: 0.081
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.